Agenda

schedule & speakers

Day 1

Thursday, June 20^th 2024

8h00

Registration and welcome coffee

8h45

Welcome Address - Einstein Auditorium

9h00

OPENING KEYNOTE LECTURES - Einstein Auditorium

Next generation bispecific antibodies and antibody fusion proteins for cancer immunotherapy

Christian Klein
Distinguished Scientist, is Department Head Cancer Immunotherapy Discovery 3, Head Oncology Programs & Site Head Roche Innovation Center Zurich
Roche pRED, Switzerland

Clinical development of bispecific antibodies and ADCs: toxicity mitigation and activity optimization strategies in expanded phase I trials

Elisa Fontana
MD, PhD, Hospital Medical Director
The Sarah Cannon Research Institute in London, UK

10h00

Coffee Break at Exhibition Hall

10h30

Paving the way for the next-generation of Antibodies & New Modalities - Einstein Auditorium

Session I

KnotBodies: creating Ion Channel Modulating Antibodies by fusing Knottins in Antibody loops

John McCafferty
CEO
Maxion Therapeutics, UK

From Sugars to Solutions: Advancing Cancer Therapeutics with Glycobiology

Paula Videira
Co-founder and CTO
CellmAbs
Associate Professor and Group Leader
UCIBIO, NOVA School of Science and Technology, NOVA University Lisbon, Portugal

Engineering and characterization of ImmTAC

Peter Molloy
Senior Fellow, Protein Engineering
Immunocore Ltd, UK

Talk by

Antibody-based Cancer Therapies : latest developments - Barthez Auditorium

Bispecific Antibody Drug Conjugates (BsADCs): strategies and challenges

Alain Beck
Senior Director, Biologics CMC & developability
Pierre Fabre, France

Innovative cancer therapies based on first-in-class antibodies anti-GPCR drug conjugates

Aiphi Andrée Nguyen
CEO
Skymab Biotherapeutics, France

Title to be announced

Peter Lowe
Director Antibody Engineering
Merus, Netherlands

12h20

Lunch at Exhibition Hall

14h00

Paving the way for the next-generation of Antibodies & New Modalities - Einstein Auditorium

Session II

Exploiting the advances of soloMER biologics to deliver multi-functional products for autoimmune diseases and cancer

Caroline Barelle
CEO & founder
Elasmogen, UK

De novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization

Stefan Zielonka
Global Head of Antibody Discovery & Protein Engineering
Merck Healthcare KGaA
Professor of Biomolecular Immunotherapy
Technical University of Darmstadt, Germany

Avidity Engineering : a next frontier in the development of differentiating antibody therapeutics

Simone Oostindie
Director Research & Discovery
GYES, Netherlands

Discovery and Development on Non-IgG based antibodies treatments - Barthez Auditorium

Using IgE based antibodies to treat cancer

Elizabeth Hardaker
VP of Biology
Epsilogen, UK

Monoclonal IgA antibody Therapy

Mitchell Evers
Antibody Scientist
Utrecht University, Netherlands

Streamlining Therapeutic Antibody Development with a Homogeneous Bioluminescent Immunoassay for Signaling Pathway Analysis

Hicham Zegzouti
Senior Research Scientist - Group Leader
Promega, USA

16h00

Pitch Session : Innovative Approaches and New trend Technologies - Einstein Auditorium

Call for abstracts until April 12^th, 2024

17h00

Round table - Enhancing Investment Understanding - Einstein Auditorium

17h50

Investor's Pitch - Einstein Auditorium

(Panel added soon)

Apply until May 12^th, 2024

19h00

Poster Presentation - Dinner Cocktail Reception at Exhibition Hall

20h30

Announcement of « BEST POSTER » by Biothérapie Innovation Occitanie

21h00

End of DAY 1

Day 2

Friday, June 21^st 2024

8h00

Welcome coffee

8h30

Efficacity and safety from preclinical to FIH trials - Einstein Auditorium

Session I

Feasibility Assessment in Therapeutic Antibody Development: Leveraging PK/PD Modeling to Navigate Challenges and Mitigate Pitfalls

Lionel Renaud
PK/PD and Systems Pharmacology modeler
Lyo-X, Switzerland

From preclinical to clinical: PK-PD modelling of an antibody drug conjugate for therapeutic index prediction

Laurence del Frari
Pharmacokineticist, Modeling & Simulation
Pierre Fabre, France

Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate in patients with relapsed or refractory acute leukemias

Pierre Launay
Co-founder & COO
Inatherys, France

Talk by

Non-oncology diseases/next generation of immunotherapies - Barthez Auditorium

The role of broadly neutralizing antibodies in HIV cure strategies

Ole Søgaard
Professor
Institut for Klinisk Medicin, Aarhus University, Denmark

Multimeric complexes to unlock the therapeutic potential of innate immunity

Carole Seguin-Devaux
Head of Research Unit
Luxemburg Institut of Health, Luxemburg

Immunotherapy for SARS-CoV2 infections

Mireia Pelegrin
DR-CNRS, Head of Antibodies, Immunomodulation and Immunotherapy group
IRMB-INSERM U1183-CHU Saint Eloi, France

10h00

Coffee Break at Exhibition Hall

10h30

Efficacity and safety from preclinical to FIH trials - Einstein Auditorium

Session II

Pharmacokinetics strategies to First in Human for different biotherapy modalities

Antoine Deslandes
Global Head of Pharmacokinetics for Devices & Biotherapeutics
SANOFI, France

Title to be announced

Alex Phipps
Executive Director. Head of Clinical Pharmacology and Quantitative Pharmacology (CPQP) - Oncology
AstraZeneca, UK

AI and Machine Learning for Antibody discovery and Optimization - Barthez Auditorium

Computational Approaches to Antibody Optimization and Humanization

Pietro Sormanni
Group Leader, Royal Society Univ. Research Fellow
University of Cambridge, UK

Towards an Integrated Platform for Antibody Discovery

Andrew Phillips
Head of Biologics AI Platform
SANOFI, UK

Title to be announced

Thomas Bourquard
CSO and co-founder
MabSilico, France

12h10

Lunch at Exhibition Hall

14h00

Advancing new Antibodies approaches into the Clinic - Einstein Auditorium

First-in-Class anti-ChemR23 pro-resolutive agonist mAbs triggers the Resolution of chronic Inflammation

Nicolas Poirier
CEO
Ose Immunotherapeutics, France

Next-generation bispecific T cell engagers with built-in autoregulation to prevent treatment-related adverse events in adoptive T cell immunotherapies